SEC Form 4 · accession 0001209191-18-050824
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Maraganore
Director
Period of report
Sep 11, 2018
Accepted (ET)
Sep 13, 2018 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Sep 11, 2018 | S | 11,155 | $72.52 | D | 38,609 | D | |
| Common stockF2 | Sep 11, 2018 | S | 2,400 | $73.82 | D | 36,209 | D | |
| Common stockF3 | Sep 12, 2018 | S | 14,162 | $71.74 | D | 22,047 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $72.27 to $72.89. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F2The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $73.33 to $74.25. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $71.70 to $72.17. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.